EICHOR
● Active Not Recruiting
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Condition: Diffuse Cutaneous Systemic Sclerosis · Interstitial Lung Disease · Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
About this study
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (95)
| Mayo Clinic - Scottsdale ( Site 4014) | Phoenix, Arizona, United States | — |
| Pacific Arthritis Care Center ( Site 4008) | Los Angeles, California, United States | — |
| Cedars Sinai Medical Center ( Site 4010) | Los Angeles, California, United States | — |
| UCLA School of Medicine ( Site 4006) | Los Angeles, California, United States | — |
| Stanford Health Care ( Site 4009) | Palo Alto, California, United States | — |
| National Jewish Health Medical Center ( Site 4015) | Denver, Colorado, United States | — |
| Yale University ( Site 4017) | New Haven, Connecticut, United States | — |
| MedStar Georgetown University Hospital ( Site 4005) | Washington D.C., District of Columbia, United States | — |
| Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018) | Baltimore, Maryland, United States | — |
| Massachusetts General Hospital ( Site 4003) | Boston, Massachusetts, United States | — |
| Boston University School of Medicine ( Site 4021) | Boston, Massachusetts, United States | — |
| University of Michigan Hospital ( Site 4001) | Ann Arbor, Michigan, United States | — |
+ 83 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05270668